Evidence map›Paper›PMID 39164787›Full record

ReviewMilitary Medical Research2024

Intelligent medicine in focus: the 5 stages of evolution in robot-assisted surgery for prostate cancer in the past 20 years and future implications.

Jia-Kun Li, Tong Tang, Hui Zong, Er-Man Wu, Jing Zhao, Rong-Rong Wu, Xiao-Nan Zheng, Heng Zhang, Yi-Fan Li, Xiang-Hong Zhou and 12 more

Abstract readReview
In one paragraph

Review in Military Medical Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. European journal of medical research · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jia-Kun Li *Department of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Tong Tang *Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Hui Zong *Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Er-Man WuInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jing ZhaoInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Rong-Rong WuInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiao-Nan ZhengDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Heng ZhangDepartment of Radiology, National Clinical Research Center for Geriatric Diseases/the Second Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Yi-Fan LiDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiang-Hong ZhouDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Chi-Chen ZhangDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zi-Long ZhangDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yi-Hang ZhangDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wei-Zhe FengInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yi ZhouInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jiao WangInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qi-Yu ZhuDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qi DengDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jia-Ming ZhengDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lu YangDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qiang WeiDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. weiqiang163163@163.com.
Bai-Rong ShenInstitutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China. bairong.shen@scu.edu.cn.ORCID 0000-0003-2899-1531

Funding

Fundamental Research Funds for the Central Universities 2023SCU12057National Natural Science Foundation of China 32270690National Natural Science Foundation of China 82372831National Natural Science Foundation of China 82373106
6 · The paper itself

Abstract

Robot-assisted surgery has evolved into a crucial treatment for prostate cancer (PCa). However, from its appearance to today, brain-computer interface, virtual reality, and metaverse have revolutionized the field of robot-assisted surgery for PCa, presenting both opportunities and challenges. Especially in the context of contemporary big data and precision medicine, facing the heterogeneity of PCa and the complexity of clinical problems, it still needs to be continuously upgraded and improved. Keeping this in mind, this article summarized the 5 stages of the historical development of robot-assisted surgery for PCa, encompassing the stages of emergence, promotion, development, maturity, and intelligence. Initially, safety concerns were paramount, but subsequent research and engineering advancements have focused on enhancing device efficacy, surgical technology, and achieving precise multi modal treatment. The dominance of da Vinci robot-assisted surgical system has seen this evolution intimately tied to its successive versions. In the future, robot-assisted surgery for PCa will move towards intelligence, promising improved patient outcomes and personalized therapy, alongside formidable challenges. To guide future development, we propose 10 significant prospects spanning clinical, research, engineering, materials, social, and economic domains, envisioning a future era of artificial intelligence in the surgical treatment of PCa.

Indexed as

Prostatic NeoplasmsRobotic Surgical ProceduresArtificial IntelligenceHumansMaleIntelligent medicineProstate cancerRobot-assisted radical prostatectomyRobotic surgical system

Identifiers

PMID39164787
PMCPMC11337898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.